As a healthcare provider, we only prescribe medications that have been proven to be safe and effective after extensive clinical trials. Our clinicians will work with you to define the optimum time for you to stay on the prescribed medication based on your individual circumstances.
​
After clinical trials proved the safety and efficacy of GLP-1 medications for diabetes, the MHRA approved semaglutide for the long-term treatment of obesity. These trials also demonstrated that the medication reduced the risk of adverse cardiovascular events including a heart attack or stroke.

Liraglutide, another GLP-1 medication, is also approved for the treatment of obesity. Treatment with liraglutide has also been shown to significantly improve systolic blood pressure and waist circumference compared with placebo.

More recently, tirzepatide, a dual GIP and GLP-1 receptor agonist was approved by the MHRA. Similar to semaglutide, the initial trials demonstrated the safety and efficacy of tirzepatide for use in diabetes, before being approved for weight management. The side effect profile for tirzepatide is similar to that of semaglutide, but the trial data showed greater weight loss over a similar period of time. The weight reduction is also accompanied by improvements in cardiovascular and metabolic risk factors including blood pressure, waist circumference and lipid levels.